Molecular Subtypes of Breast Cancer: Long-term Incidence Trends and Prognostic Differences

Background: Secular trends in incidence and prognosis of molecular breast cancer subtypes are poorly described. We studied long-term trends in a population of Norwegian women born 1886–1977. Methods: A total of 52,949 women were followed for breast cancer incidence, and 1,423 tumors were reclassified into molecular subtypes using IHC and in situ hybridization. We compared incidence rates among women born 1886–1928 and 1929–1977, estimated age-specific incidence rate ratios (IRR), and performed multiple imputations to account for unknown subtype. Prognosis was compared for women diagnosed before 1995 and in 1995 or later, estimating cumulative risk of death and HRs. Results: Between 50 and 69 years of age, incidence rates of Luminal A and Luminal B (HER2−) were higher among women born in 1929 or later, compared with before 1929 [IRRs 50–54 years; after imputations: 3.5; 95% confidence interval (CI), 1.8–6.9 and 2.5; 95% CI, 1.2–5.2, respectively], with no clear differences for other subtypes. Rates of death were lower in women diagnosed in 1995 or later, compared to before 1995, for Luminal A (HR 0.4; 95% CI, 0.3–0.5), Luminal B (HER2−; HR 0.5; 95% CI, 0.3–0.7), and Basal phenotype (HR 0.4; 95% CI, 0.2–0.9). Conclusions: We found a strong secular incidence increase restricted to Luminal A and Luminal B (HER2−) subtypes, combined with a markedly improved prognosis for these subtypes and for the Basal phenotype. Impact: This study documents a clear secular increase in incidence and a concomitant improved prognosis for specific molecular breast cancer subtypes. Cancer Epidemiol Biomarkers Prev; 25(12); 1625–34. ©2016 AACR.

[1]  R. Gelber,et al.  Tailoring therapies—improving the management of early breast cancer: St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2015 , 2015, Annals of oncology : official journal of the European Society for Medical Oncology.

[2]  Kevin A. Henry,et al.  Annual Report to the Nation on the Status of Cancer, 1975-2011, Featuring Incidence of Breast Cancer Subtypes by Race/Ethnicity, Poverty, and State , 2015, Journal of the National Cancer Institute.

[3]  L. Vatten,et al.  Anthropometric factors and risk of molecular breast cancer subtypes among postmenopausal Norwegian women , 2014, International journal of cancer.

[4]  C. Perou,et al.  Age-specific changes in intrinsic breast cancer subtypes: a focus on older women. , 2014, The oncologist.

[5]  L. Vatten,et al.  Modern mammography screening and breast cancer mortality: population study , 2014, BMJ : British Medical Journal.

[6]  L. Vatten,et al.  Reproductive history and the risk of molecular breast cancer subtypes in a prospective study of Norwegian women , 2014, Cancer Causes & Control.

[7]  John M S Bartlett,et al.  Recommendations for human epidermal growth factor receptor 2 testing in breast cancer: American Society of Clinical Oncology/College of American Pathologists clinical practice guideline update. , 2014, Archives of pathology & laboratory medicine.

[8]  V. Speirs,et al.  The value of archival tissue blocks in understanding breast cancer biology , 2013, Journal of Clinical Pathology.

[9]  C. Perou,et al.  Personalizing the treatment of women with early breast cancer: highlights of the St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2013 , 2013, Annals of oncology : official journal of the European Society for Medical Oncology.

[10]  L. Vatten,et al.  Molecular subtypes, histopathological grade and survival in a historic cohort of breast cancer patients , 2013, Breast Cancer Research and Treatment.

[11]  B. Møller,et al.  Breast cancer mortality in participants of the Norwegian Breast Cancer Screening Program , 2013, Cancer.

[12]  C. Ambrosone,et al.  Time-trends in survival in young women with breast cancer in a SEER population-based study , 2013, Breast Cancer Research and Treatment.

[13]  M. Rinaldo,et al.  Molecular profiles of screen detected vs. symptomatic breast cancer and their impact on survival: results from a clinical series , 2013, BMC Cancer.

[14]  S. Hofvind,et al.  Breast cancer incidence trends in Norway—explained by hormone therapy or mammographic screening? , 2012, International journal of cancer.

[15]  L. Vatten,et al.  Understanding recent trends in incidence of invasive breast cancer in Norway: age-period-cohort analysis based on registry data on mammography screening and hormone treatment use , 2012, BMJ : British Medical Journal.

[16]  Jack Cuzick,et al.  Assessment of Ki67 in breast cancer: recommendations from the International Ki67 in Breast Cancer working group. , 2011, Journal of the National Cancer Institute.

[17]  M. Kumle,et al.  Mammography activity in Norway 1983 to 2008 , 2011, Acta oncologica.

[18]  Philippe Autier,et al.  Breast cancer mortality in neighbouring European countries with different levels of screening but similar access to treatment: trend analysis of WHO mortality database , 2011, BMJ : British Medical Journal.

[19]  R. Gelber,et al.  Strategies for subtypes—dealing with the diversity of breast cancer: highlights of the St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2011 , 2011, Annals of oncology : official journal of the European Society for Medical Oncology.

[20]  F M Blows,et al.  Comparison of methods for handling missing data on immunohistochemical markers in survival analysis of breast cancer , 2011, British Journal of Cancer.

[21]  L. Bernstein,et al.  Menopausal Hormone Therapy and Subsequent Risk of Specific Invasive Breast Cancer Subtypes in the California Teachers Study , 2010, Cancer Epidemiology, Biomarkers & Prevention.

[22]  Anthony Rhodes,et al.  American Society of Clinical Oncology/College of American Pathologists guideline recommendations for immunohistochemical testing of estrogen and progesterone receptors in breast cancer. , 2010, Archives of pathology & laboratory medicine.

[23]  Päivi Heikkilä,et al.  Subtyping of Breast Cancer by Immunohistochemistry to Investigate a Relationship between Subtype and Short and Long Term Survival: A Collaborative Analysis of Data for 10,159 Cases from 12 Studies , 2010, PLoS medicine.

[24]  S. Duffy,et al.  Molecular characteristics of screen-detected vs symptomatic breast cancers and their impact on survival , 2009, British Journal of Cancer.

[25]  A. Auvinen,et al.  HER-2 positive breast cancer: decreasing proportion but stable incidence in Finnish population from 1982 to 2005 , 2009, Breast Cancer Research.

[26]  Charles M. Perou,et al.  Ki67 Index, HER2 Status, and Prognosis of Patients With Luminal B Breast Cancer , 2009, Journal of the National Cancer Institute.

[27]  P. Porter,et al.  Reproductive and hormonal risk factors for postmenopausal luminal, HER‐2‐overexpressing, and triple‐negative breast cancer , 2009, Cancer.

[28]  C. Perou,et al.  Breast cancer subtypes and response to docetaxel in node-positive breast cancer: use of an immunohistochemical definition in the BCIRG 001 trial. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[29]  V. Kataja,et al.  Molecular Subtypes of Breast Cancers Detected in Mammography Screening and Outside of Screening , 2008, Clinical Cancer Research.

[30]  C. Perou,et al.  Epidemiology of basal-like breast cancer , 2008, Breast Cancer Research and Treatment.

[31]  K. Hess,et al.  Response to neoadjuvant therapy and long-term survival in patients with triple-negative breast cancer. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[32]  Robert N Hoover,et al.  Breast cancer incidence, 1980-2006: combined roles of menopausal hormone therapy, screening mammography, and estrogen receptor status. , 2007, Journal of the National Cancer Institute.

[33]  Bingshu E. Chen,et al.  Breast cancer mortality trends in the United States according to estrogen receptor status and age at diagnosis. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[34]  F. Berrino,et al.  Time trends of breast cancer survival in Europe in relation to incidence and mortality , 2006, International journal of cancer.

[35]  T. Stijnen,et al.  Review: a gentle introduction to imputation of missing values. , 2006, Journal of clinical epidemiology.

[36]  D. Berry,et al.  Effect of screening and adjuvant therapy on mortality from breast cancer. , 2006, The New England journal of medicine.

[37]  D. Berry,et al.  Effect of screening and adjuvant therapy on mortality from breast cancer , 2005 .

[38]  W. Sauerbrei,et al.  Reporting recommendations for tumor marker prognostic studies (REMARK). , 2005, Journal of the National Cancer Institute.

[39]  W. Foulkes,et al.  A Basal Epithelial Phenotype Is More Frequent in Interval Breast Cancers Compared with Screen Detected Tumors , 2005, Cancer Epidemiology Biomarkers & Prevention.

[40]  R. Tibshirani,et al.  Repeated observation of breast tumor subtypes in independent gene expression data sets , 2003, Proceedings of the National Academy of Sciences of the United States of America.

[41]  Charles Kooperberg,et al.  Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results From the Women's Health Initiative randomized controlled trial. , 2002, JAMA.

[42]  R. Tibshirani,et al.  Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications , 2001, Proceedings of the National Academy of Sciences of the United States of America.

[43]  Christian A. Rees,et al.  Molecular portraits of human breast tumours , 2000, Nature.

[44]  E. Vittinghoff,et al.  Postmenopausal Hormone Therapy Increases Risk for Venous Thromboembolic Disease: The Heart and Estrogen/progestin Replacement Study , 2000, Annals of Internal Medicine.

[45]  Mike Clarke,et al.  Tamoxifen for early breast cancer: an overview of the randomised trials , 1998, The Lancet.

[46]  I. Ellis,et al.  Pathological prognostic factors in breast cancer. I. The value of histological grade in breast cancer: experience from a large study with long-term follow-up. , 2002, Histopathology.

[47]  R. Peto,et al.  Effects of adjuvant tamoxifen and of cytotoxic therapy on mortality in early breast cancer. An overview of 61 randomized trials among 28,896 women. , 1989, The New England journal of medicine.

[48]  Ivar Heuch,et al.  A prospective study of reproductive factors and breast cancer. II. Age at first and last birth. , 1987, American journal of epidemiology.

[49]  Ivar Heuch,et al.  A prospective study of reproductive factors and breast cancer. I. Parity. , 1987, American journal of epidemiology.

[50]  K. Gelmon,et al.  Comparison of breast cancer recurrence and outcome patterns between patients treated from 1986 to 1992 and from 2004 to 2008. , 2015, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[51]  Sunil R. Lakhani,et al.  WHO classification of tumours of the breast , 2012 .

[52]  G. Colditz,et al.  Traditional breast cancer risk factors in relation to molecular subtypes of breast cancer , 2011, Breast Cancer Research and Treatment.

[53]  B. Møller,et al.  Cancer incidence, mortality, survival and prevalence in Norway , 2011 .

[54]  Arnulf Langhammer,et al.  The Nord-Trøndelag Health Study 1995-97 (HUNT 2): Objectives, contents, methods and participation , 2003 .

[55]  K. Malone,et al.  Incidence of invasive breast cancer by hormone receptor status from 1992 to 1998. , 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[56]  R. Elledge,et al.  Rising levels of estrogen receptor in breast cancer over 2 decades. , 1994, Cancer.

[57]  Jack Cuzick,et al.  Effects of adjuvant tamoxifen and of cytotoxic therapy on mortality in early breast cancer. An overview of 61 randomized trials among 28,896 women , 1988 .